

The history of stress hyperglycaemia

¹A Balasanthiran, ²K Shotliff

¹NIHR CLAHRC Northwest London, Imperial College London, Chelsea & Westminster Hospital NHS Foundation Trust, London, UK; ²Beta Cell Centre for Diabetes, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK

ABSTRACT Stress hyperglycaemia, is a common phenomenon, frequently associated with adverse outcomes in a number of prevalent conditions including myocardial infarction and stroke. Knowledge on stress hyperglycaemia evolved in tandem with knowledge relating to homeostasis, stress and disease and involved some of the world's most eminent thinkers. Despite this, it still remains under-recognised.

This paper illustrates significant points in the history of stress hyperglycaemia, from antiquity through to the present day, as well as the challenges faced in translating research into clinical benefit for patients. Profiles of significant protagonists including Claude Bernard, Walter Cannon and Hans Seyle are presented, as well their roles in the emergence of modern-day terminology and pathophysiological models. Major themes such as 'fight or flight' and homeostasis are central to this discussion.

Closer to the present day, the role of stress hyperglycaemia in a number of common medical conditions is explored in more detail. Contention around evidence for treatment and the future risk of diabetes mellitus are also discussed.

KEYWORDS Claude Bernard, Walter Cannon, myocardial infarction, stress hyperglycaemia, stroke

DECLARATION OF INTERESTS No conflict of interest declared

INTRODUCTION

Stress hyperglycaemia, defined as 'transient hyperglycaemia during illness',¹ is a common condition. Hyperglycaemia typically resolves as the illness dissipates, although in a proportion of people it may indicate unrecognised diabetes mellitus.² A number of studies have shown that stress hyperglycaemia is associated with poor outcomes across a wide range of conditions.^{3,4,5} Despite this, best management of the condition is unclear and remains the subject of active research.

This paper explores views on hyperglycaemia, stress and disease as they emerge in antiquity and evolve through to the current day. The story incorporates aspects from the modern fields of biochemistry, mechanics, physiology and medicine.

A glimpse into the history of this intriguing condition provides insights into the evolution of major themes in medicine such as homeostasis, as well as the challenges involved in converting research, even that conducted by the world's most eminent thinkers, into direct patient benefit. The staggered accumulation of knowledge described is perhaps not surprising given the diversity of research conducted and the substantial clinical concepts involved.

The first written descriptions relating to the symptoms of hyperglycaemia appear to have been found in the

Ebers Papyrus, an ancient Egyptian text relating to the practice of medicine, written around 1550 BCE. In ancient Greece, Hippocrates, 'the father of medicine', described polyuria and wasting of the body. His disciple, Aretaeus of Cappadocia, a Greek physician, was the first to use the term 'diabetes', derived from the Greek word for 'siphon', in relation to these symptoms.^{6,7}

In parallel, concepts relating to homeostasis, stress and disease were beginning to emerge. Ancient Greeks such as Heraclitus (540–480BC) and Empedocles (495–435 BC) used terms such as 'balance' and 'equilibrium' to define the basic characteristics of life; the emerging view being that the ability to change or react to threatening forces was pivotal in restoring harmony and enabling survival of the organism. Hippocrates elaborated further by describing health as harmony, and disease as disharmony.⁸

It took until the 17th century for the clinical features of diabetes and glycosuria to be well documented. A number of clinicians had described the urine of polyuric patients as sweet, honey-tasting and attractive to flies and ants.^{7,9} Despite this, it was some time before hyperglycaemia was identified.

In Europe, Thomas Willis (1621–1675), who studied medicine at Oxford, referred to diabetes as the 'pissing evil'¹⁰ but also went a step further to suggest that the condition was primarily a disease of the blood.⁶

Correspondence to A Balasanthiran
 NIHR CLAHRC for Northwest
 London
 Imperial College London
 Chelsea & Westminster Hospital
 NHS Foundation Trust
 369 Fulham Road
 London, SW10 9NH
 UK

e-mail a.balasanthiran@imperial.ac.uk

Matthew Dobson (1734–1784) advanced understanding further by experimenting on the urine and blood of Peter Dickonson, a 33-year-old man with symptoms of uncontrolled diabetes.⁷ As well as confirming that his urine contained a substance indistinguishable from sugar,⁶ he also identified that the blood serum was sweet to taste. Following further experimentation, he concluded that diabetic urine always contains sugar which is not formed in the kidney as previously thought but ‘existed in the serum of the blood’.⁷ This important observation, obvious as it may seem now, paved the way for the modern understanding of diabetes and hyperglycaemia.

Particularly important here, as is typical of this narrative and many others in medicine, the flow of knowledge was staggered. Dobson published his research in the journal of a London medical society with a handful of members who ‘met on alternate Monday evenings at the Mitre Tavern in Fleet street’ and the findings were debated for some time.⁹ Dobson’s discovery was, among many things, pivotal in the progress of diagnostics for hyperglycaemia.

19TH CENTURY

Major developments in the concept of stress hyperglycaemia occurred during the 19th century, with the beginning of the experimental period in diabetes and work defining modern medical views of stress conducted by Claude Bernard (Fig 1) (1813–1878) and Walter Cannon (1871–1945).

Bernard is often described as the greatest physiologist of his time and founder of experimental medicine. He was born in Saint-Julien in France and originally pursued a career in literature. Having been dissuaded from this course by a literary critic,¹¹ he eventually trained in medicine. When he died, his distinguished contribution to the field accorded him a public funeral – an honour that France had never before bestowed on a man of science.¹² Early in his career, Bernard developed respect for clinicians such as François Magendie,^{11,12} who cultivated his interest in nutrition, and Pierre Rayer¹³ who had particular expertise in diabetes. It is perhaps these influences, which encouraged Bernard to closely scrutinise glucose metabolism. His discovery – that gastric juices were capable of digesting cane sugar and starch into glucose – would eventually form part of his thesis.¹⁴

In 1848 he expanded his research into this field, developing a particular interest in the distribution of glucose through the body. He was intrigued to detect glucose in the blood of fasting humans and concluded, through rigorous experimentation and careful deduction, that the liver was capable of synthesising glucose, even in fasting humans.⁷ He named the substance responsible for this ‘glycogene’.^{11,14}




FIGURE 1 Claude Bernard (Wellcome Library, London)

That the liver was capable of synthesising glucose was a controversial observation, in direct opposition to two commonly held beliefs: the inability of animals to synthesise nutrients⁷ and ‘one-organ one-function’. In disproving both these theories, Bernard set the scene for a new way of thinking which ultimately led to the discovery of further ‘glands of internal secretion’ and the definition of the modern endocrine system.¹⁵

Bernard also contributed significantly to modern medical views on stress by appreciating that, while organisms are closely responsive to their external environment, they also strive to maintain a stable and independent internal environment or ‘Milieu Interieur’.¹² This was encapsulated in his statement, ‘constancy and stability of the internal environment is the condition that life should be free and independent’.^{8,16} In 1855, by applying these principles to medicine, Bernard was the first to report data relating to hyperglycaemia in critically ill patients.¹⁷

The other great 19th century master of this field was Walter Bradford Cannon (Fig 2) who was born in Wisconsin in 1871.¹⁸ As Claude Bernard before him, he was credited with an open, enquiring mind and his lifetime achievements eventually led to him being recognised as one of America’s leading physiologists.

From an early age, Cannon displayed an interest in the biological sciences and absorbed himself in debates between traditionalists and Darwinists. He struggled with a conflict between his religious and scientific beliefs, eventually leading him to reject the ideals of his family’s



FIGURE 2 Walter Bradford Cannon (Wellcome Library, London)

faith. He reports being challenged by the church following this decision; 'he wanted to know what right I had, as a mere youth, to set up my opinion against the opinion of great scholars'.¹⁹

Despite this early discouragement, Cannon went on to distinguish himself academically, and was accepted into Harvard Medical School in 1896.²⁰ Here, he sought out opportunities for research and was enrolled by the professor of physiology to use X-rays, a new discovery, to explore the mechanism of swallowing.²⁰⁻²² During the course of this research, an astute observation, that anxiety led to a change in stomach motility, piqued an interest in the relationship between emotion and physiology.¹⁶ This culminated in the discovery that major emotions involve the excitation of the sympathetic nervous system, increased secretion of adrenaline and a collection of physiological changes, now recognised as the 'stress response'.²⁰ Cannon coined the term 'fight or flight' in a 1915 publication²³ to describe these changes.

20TH CENTURY

Some 20 years later, and with the benefit of a significant body of work measuring blood variables, Cannon expanded Bernard's concept of the milieu interieur to 'homeostasis';^{8,16} a maintenance of physiological variables within acceptable, narrow ranges, rather than more precise fixed values.²¹ Laying the foundations for modern understanding of stress hyperglycaemia, a section of

Cannon's successful 1932 publication, *The Wisdom of the Body*²⁴ describes how a state of 'pseudo or sham rage' was induced through the abrupt cessation of anaesthesia in decorticate animals. In addition to the signs of sympathetic innervation associated with this stressful event, an increase in blood glucose to five times the normal percentage was observed.

During this period, Cannon's research programme grew considerably and, by the end of his 36-year professorship at Harvard Medical School, he would work with over 400 graduate students and colleagues. He died three years after retirement, a major public and political figure, described by Ralph W Gerard, a fellow former president of the American Physiological Association, as 'the greatest American physiologist'.²⁵

The next important development originates from endocrinologist Hans Seyle, who was born in Vienna in 1907. Seyle trained in medicine at the German University of Prague where he graduated first in his class. As a medical student, he noted a constellation of signs and symptoms common to sick patients, regardless of the disease and subsequently popularised the term 'stress' within this context, using it to describe the response of the body to a wide range of stressors.²³

Following extensive research, he refined his observations to propose the General Adaptation Syndrome, a description of three stages in the response to a stressor:

- The alarm reaction
- Stage of resistance
- Stage of exhaustion

As highlighted by the 'stage of exhaustion', Seyle concluded that, 'the ability of living organisms to adapt themselves to changes in their surroundings is a finite quality'.²⁶

During this period, the term 'adaptation' was widely used in physiological, psychological and sociological literature. The English biologist Herbert Spencer (1820–1903) claimed that all 'evil results from the non-adaptation of constitution to conditions'.¹⁵ Seyle himself appeared to shift his vocabulary around 1950 to 'reconceptualize stress, referring to it not merely as an external trigger of internal processes but also as a physiological or pathological process itself'.¹⁵ It is thought that this shift in language from adaptation to stress may have been preferred by Seyle for various reasons, including that it positioned his work more closely to that of Walter Cannon, as well as those studying anxiety and illness in occupational settings where the term 'stress' was already popularised.¹⁵

A large amount of Seyle's work is relevant to modern understanding of stress hyperglycaemia. Aside from popularising the term 'stress' within the medical

vocabulary, he also described how physiological features of 'defense' to and 'damage' from stress may coexist, noting that 'some of the hormones produced during stress have definitely toxic effects'. The key role of the hypothalamic-pituitary-adrenal (HPA) axis in orchestrating responses was also highlighted.²⁶

Seyle dedicated most of his life to researching stress in medicine and, by the time of his death in 1982, left an incredible legacy of over 1700 papers and 39 books. His two major books *The Stress of Life* (1956) and *Stress Without Distress* (1974) sold millions of copies worldwide.

The early 20th century also saw an increasing number of reports examining hyperglycaemia to extreme stressors such as asphyxia²⁷ (1919) and pontine decerebration²⁸ (1933). Among other things, these early experiments highlighted the importance of counter-regulatory hormones such as epinephrine and hepatic gluconeogenesis in such scenarios.

Various terminologies that could be considered precursors to the modern term 'stress hyperglycaemia' began to emerge during this period (Figure 3).²⁸⁻³¹ In these cases, hyperglycaemia was often precipitated during animal experimentation through the use of various stressors. As described previously, Claude Bernard was the first to report stress hyperglycaemia in association with an acute human illness (1855).¹⁷ An American physician and professor, Franklin McLean then published a paper in 1914³² that described various cases of 'transitory hyperglycaemia and glycosuria', which he said 'are not to be regarded as diabetic symptoms'. Eight years later, it was observed that 'coronary artery disease produces by itself a glycosuria that need not be indicative of diabetes'.³³ This was followed by a number of publications reporting 'transient glycosuria' in association with coronary thrombosis.³⁴⁻⁴² In one case, 12 patients were followed up ten years after their coronary event and found to have normal glucose tolerance curves.⁴²

Although the distinction was clearly made between this apparent 'transient glycosuria' syndrome and diabetes, it was another 25 years before the term 'stress hyperglycaemia' appeared in the title of a publication.⁴³ In this paper, 26 patients with stress hyperglycaemia were described and a number of important observations, illustrative of 20th century knowledge into this condition, are made. First, a variety of acute illnesses including myocardial infarction and cerebral haemorrhage are mentioned in association with stress hyperglycaemia. Second, 'hyperglycaemia and glycosuria disappeared with clinical improvement' in all but three of these patients within a few days of the acute episode. This statement is closely aligned to modern definitions of stress hyperglycaemia. Follow-up studies of this nature are now an established investigative tool in this condition. Third, the three patients in whom hyperglycaemia did not




FIGURE 3 Various precursors to the term 'stress hyperglycaemia'

resolve were described as having 'latent diabetes that became manifest following the acute disorder'. This was also reported by other authors during this period,^{39,41,42,44} and is now a well-recognised outcome. Finally, having previously reported raised pyruvic acid levels in association with emotional stress,⁴⁵ the authors note that levels are 'markedly elevated' in people with stress hyperglycaemia compared to those with diabetes. Since this publication, many more biomarkers have been examined in stress hyperglycaemia. They are largely selected for their ability to demonstrate a stress response or predict development of future diabetes.⁴⁶

Another important paper to emerge during this period (1951) was co-authored by Max Ellenburg, a former president of the American Diabetes Association.⁴⁷ In this paper, '75 consecutive autopsied cases of coronary thrombosis' were studied and associations between hyperglycaemia, clinical course and histological findings were reported. Of note, people with stress hyperglycaemia (reported as 'nondiabetic cases with hyperglycaemia') suffered more profound shock and a 'stormier' clinical course. Although it is now well recognised, this was one of the first papers to highlight links between stress hyperglycaemia and adverse clinical outcomes, reporting a higher incidence of conduction pathway defects and arrhythmias and an average survival of 6.3 days compared to 20.3 days for those with normoglycaemia. Histological findings also indicated more extensive areas of infarct in the hyperglycaemic group as well as central liver cell necrosis. Based on contemporary knowledge, largely gained through animal experimentation, the authors presented their 'crude picture' of the mechanisms leading to stress hyperglycaemia highlighting adrenaline-driven hepatic glycogenolysis and gluconeogenesis. In fact, gluconeogenesis is later recognised as one of the most important contributing factors to stress hyperglycaemia.¹ The authors also draw parallels between deteriorating diabetes and stress hyperglycaemia: 'the mechanism of increased severity of the diabetes in cases

with coronary thrombosis is identical with the mechanism of hyperglycaemia in non-diabetics with coronary thrombosis'. Deteriorating glycaemic control in acutely unwell people with established diabetes, now considered by some as a version of stress hyperglycaemia, is often under-recognised.

During the 1950s, the term 'latent diabetes' began to emerge to describe individuals in whom evidence of impaired glucose tolerance only appeared with the administration of cortisone.^{48,49} In addition to such provocation, a publication during this period suggested that 'stress situations' such as infection, pregnancy and obesity may also unmask latent diabetes.⁴⁸ In this context, it is suggested that 'stress' acts as a catalyst toward the development of 'overt diabetes'. While the modern definition of stress hyperglycaemia refers to a 'transient' phenomenon, some research suggests that a proportion of those with stress hyperglycaemia go on to develop overt diabetes during follow-up.^{50,51}

Another important condition coming to light in parallel with stress hyperglycaemia was gestational diabetes. A transient diabetes, associated with pregnancy, was described as far back as 1882.⁵² Subsequent work demonstrated various similarities between gestational diabetes and stress hyperglycaemia: i) a clear association with adverse outcomes;^{53,54} ii) a propensity to develop diabetes in the years following pregnancy/period of stress.^{55,56} Stress hyperglycaemia and gestational diabetes differ, however, in that the latter has recognised definitions, endorsed by speciality societies, established screening procedures and well-rehearsed modes of treatment.⁵³ In addition, unlike stress hyperglycaemia, the pathophysiology of gestational diabetes was examined as far back as 1898 with dedicated experimentation.^{57,58}

By the early 1970s, more information relating to the pathogenesis of stress hyperglycaemia had emerged. A paper investigating the metabolic response in myocardial infarction, described as a 'severe trauma...an acute emotional stress', drew parallels between the hormonal changes found in this condition and other 'medical and surgical diseases' outlining:⁵⁹

- Increased plasma concentrations of adrenocorticotrophic hormone and cortisol
- High levels of urinary adrenaline and noradrenaline
- Failure of response of plasma immunoreactive insulin to intravenous glucose
- Failure of rise in plasma insulin level in spite of stress hyperglycaemia

Other key papers of the 20th century examined clinical outcomes,⁶⁰ prediction tools⁶¹ and factors involved in the aetiology of stress hyperglycaemia.⁶² Myocardial infarction was a major area of interest up to this point and a paper published in 2000⁴ identified 15 studies (1966–1998)

suitable for inclusion into a meta-analysis. The findings consolidated earlier suspicions: people *without* diabetes and stress hyperglycaemia (on admission for acute myocardial infarction) are at increased risk of in-hospital mortality and congestive heart failure or cardiogenic shock. A number of mechanisms are proposed to explain this including:

- Relative insulin deficiency, increased lipolysis and excess circulating free fatty acids, toxic to ischaemic myocardium
- Osmotic diuresis leading to interference with normal compensatory mechanisms for failing left ventricle (increased end-diastolic volume leading to increased stroke volume)

Stress hyperglycaemia was also associated with an increased risk of mortality in people with diabetes although the effect was smaller than in those without diabetes.

Interest evolved in stress hyperglycaemia and stroke. From the mid 1970s, studies began to emerge reporting poor neurological outcomes and increased mortality in the context of hyperglycaemia.^{63–65} Similar reports were published in the 1990s^{66–69} and biomarker studies suggested a vital role for 'stress hormones', notably cortisol, in the intensity of hyperglycaemia as well as the overall outcome post-stroke.⁷⁰ Other studies demonstrated elevated plasma catecholamine levels although no clear link with outcomes was reported.⁷¹

The high prevalence of hyperglycaemia, recognised and unrecognised in the period preceding stroke and at time of presentation was also reported.⁷² Finally, towards the end of the 20th century, a small randomised controlled trial concluded that glucose-lowering therapy for mild to moderate hyperglycaemia (plasma glucose 7.0–17.0 mmol/L) was a safe intervention in the acute phase of stroke.⁷³

21ST CENTURY

More recently, stress hyperglycaemia has been studied in a wide range of conditions including chronic obstructive pulmonary disease,⁵ pneumonia,⁷⁴ stroke,⁷⁵ heart failure,⁷⁶ and sepsis.⁷⁷ In almost all cases, adverse outcomes have been identified in association with stress hyperglycaemia. In response, further work has aimed to improve outcomes through risk stratification and proactive management.⁷⁸

HYPERGLYCAEMIA IN INTENSIVE CARE

Several studies have suggested that people with stress hyperglycaemia have worse outcomes at a given degree of hyperglycaemia than people with diabetes.^{1,79,80} A landmark interventional study in 2001 randomly assigned 1,548 patients on a surgical intensive care unit to either

intensive insulin therapy (maintaining blood glucose 4.4–6.1 mmol/L) or conventional treatment (maintaining blood glucose 10–11.1 mmol/L with infusion of insulin only if blood glucose rose to > 11.9 mmol/L). It was concluded that intensive insulin therapy reduced mortality.⁷⁸ Further studies failed to reproduce this finding^{81,82} and several meta-analyses^{83,84} concluded that tight glycaemic control was not associated with significantly reduced hospital mortality.⁸⁵ Included in the analysis was a large, international trial of 6,104 intensive care patients concluding that intensive glucose control actually *increased* mortality.⁸⁶

A few studies specifically aimed to identify patients with stress hyperglycaemia in the intensive care setting. Of these, one found that a target glucose of 6.9 mmol/L led to a significantly reduced mortality in patients with stress hyperglycaemia but *not* diabetes. In concordance with this, mortality began to rise when mean glucose was > 7.8 mmol/L in patients without diabetes, compared to a higher threshold of 10 mmol/L in people with diabetes.⁸⁷ Similar findings have been reported in other settings and disease states and various hypotheses have been suggested to explain this.⁴ In 2002 an American group studied a mixed population of general medical patients and grouped them according to blood glucose levels and medical history (normoglycaemia, new hyperglycaemia or pre-existing diabetes). When compared to those with normoglycaemia, mortality was significantly higher in those with ‘new hyperglycaemia’ compared to those with diabetes.⁸⁸

HYPERGLYCAEMIA IN ACUTE MYOCARDIAL INFARCTION

Recent work in cardiovascular disease supports findings of the earlier mentioned meta-analysis. In a large sample of elderly patients with acute myocardial infarction, higher glucose levels were associated with a greater risk of 30-day mortality in patients without diabetes compared to patients with diabetes.⁸⁹ Longer follow-up periods have, however, resulted in variable results.^{90,92}

In addition to previous hypothesis for mechanism of harm, recent studies have concluded that stress hyperglycaemia is an independent predictor of left ventricular remodelling after anterior myocardial infarction⁹³ and may also contribute to arrhythmias.⁹⁴

There has also been a recent focus on biomarkers and tools to predict the risk of stress hyperglycaemia, future diabetes and outcomes from intervention.⁹⁵ Higher cortisol levels have been found to be predictive of the onset of stress hyperglycaemia⁹⁶ as well as of subsequent normalisation of blood glucose levels.⁹⁷ In the case of the latter it is suggested that higher cortisol levels reflect stress-precipitated hyperglycaemia whereas lower cortisol levels suggest ‘underlying glucose intolerance’ as

the most likely explanation for hyperglycaemia. Glycated haemoglobin has also been studied with varying results. One study found that hyperglycaemia and non-elevated glycated haemoglobin was associated with a poor prognosis following acute myocardial infarction whereas another study did not find any association between mortality and glycated haemoglobin.⁹⁸

A number of recent studies have examined the role of insulin intervention in myocardial infarction. This was first suggested as a treatment for acute myocardial infarction in the early 1960s⁹⁹ and subsequent trials have examined effects on mortality.¹⁰⁰ More recently, the DIGAMI-2,¹⁰¹ HI-5¹⁰² and CREATE-ECLA¹⁰³ studies did not find a benefit to this approach.

Future work may focus on the role of glucagon-like peptide I in the setting of acute myocardial infarction¹⁰⁴ as well as the role of percutaneous coronary intervention in the treatment and risk reduction of patients with stress hyperglycaemia and acute myocardial infarction.¹⁰⁵

HYPERGLYCAEMIA IN RESPIRATORY DISEASE

Another recent field of interest has been pulmonary disease. Stress hyperglycaemia is seen in up to 50% of patients hospitalised with exacerbations of chronic obstructive pulmonary disease and each 1 mmol/L increase in blood glucose has been shown to increase the absolute risk of death or prolonged hospital stay by 15%.¹⁰⁶ Prospective studies are currently underway to determine whether blood glucose control can improve chronic obstructive pulmonary disease exacerbation outcomes.¹⁰⁷

A similar picture has been identified with pneumonia. A study of 6,891 adults (2003–2009) reported hyperglycaemia in 40% of patients presenting with community acquired pneumonia. Hyperglycaemia was found to be an independent predictor of 28-, 90- and 180-day mortality with increasing glucose levels corresponding to increased risk.¹⁰⁸ Of interest, a separate study identified an association between hyperglycaemia (in ‘non-diabetic community acquired pneumonia patients’), a more pronounced inflammatory response and adverse clinical outcomes.¹⁰⁹

HYPERGLYCAEMIA IN STROKE

More evidence is now available to demonstrate how hyperglycaemia and insulin resistance exacerbate brain injury and induce cell lysis.^{110–112} The glucose profile of patients with post-stroke hyperglycaemia was also investigated in more detail using continuous glucose monitoring. ‘Early’ hyperglycaemia (≥ 7.0 mmol/L, 8 hours post-stroke) was reported in 50% of people without diabetes followed by a later hyperglycaemic phase in 27% (48–88 hour post-stroke).¹¹³

Longer term outcomes were studied in a retrospective analysis of 433 patients and it was concluded that hyperglycaemia (>10.0 mmol/L) but not diabetes per se is an independent predictor of dependency one year post-stroke.¹¹⁴ As with myocardial infarction, further evidence accumulated to suggest that hyperglycaemia is associated with worse outcomes in people without diabetes compared to those with the condition.^{4,75,115-117} Interestingly, in lacunar stroke, studies have reported that hyperglycaemia may have a protective effect¹¹⁸⁻¹²⁰ and is not associated with functional outcome, irrespective of diabetic status.¹²¹

As with other conditions, controversy exists over whether acute hyperglycaemia directly leads to worsening pathology or whether it is, in fact, an epiphenomenon. Some question why, 'glucose, the main energy substrate for the brain, causes demise of brain tissue at the time of cerebral ischaemia'.¹²² Recent magnetic resonance imaging studies seem to support a causative role for hyperglycaemia in neurological deterioration.¹¹⁰

Another area of contention in stroke is whether stress hyperglycaemia is a separate entity or, in fact, unmasked glucose intolerance. It has been reported that two thirds of those with post-stroke hyperglycaemia (but not diabetes) are diagnosed with impaired glucose tolerance or diabetes at 12 weeks,⁵⁰ while another study reported that hyperglycaemia in the setting of an acute stroke is transient in the majority of patients.⁵¹

HYPERGLYCAEMIA IN HEART FAILURE

Although links between diabetes and heart failure have been recognised for some time¹²³ and there are many studies linking stress hyperglycaemia to mortality in acute myocardial infarction, the heart failure story is not as clear. Blood glucose values have been shown to be predictive of short-term mortality in a number of studies^{76,124-126} but a large (n = 50,532) study did not find associations between admission glucose and mortality.¹²⁷ The result of a study examining the effect of insulin on outcomes is awaited.¹²⁸

CONCLUSIONS

The history of stress hyperglycaemia is complex and fascinating. The body of knowledge has accumulated over centuries and across continents, incorporating major themes such as homeostasis and 'fight or flight'. Despite the involvement of a large number of eminent thinkers, the spread and acceptance of valuable clinical knowledge has often been suboptimal, perhaps due, in part, to a staggered narrative. This problem continues today.

Enquiring minds opened up the possibility of a new disease entity, separate to diabetes. It is now established to be a common condition with studies reporting prevalence of between 16–79% of people affected, depending on the disease group and population examined.¹²⁹

It was initially believed that hyperglycaemia during stress was a benign response or epiphenomenon. As more evidence has been presented, thinking has largely (but not entirely¹³⁰) shifted towards viewing stress hyperglycaemia as a mediator of harm and a marker of poor outcomes. In the early 20th century, Hans Seyle observed that 'some of the hormones produced during stress have definitely toxic effects'. Knowledge of the underlying mechanisms of pathogenesis and harm have evolved greatly since then.^{1,131} The medical definition of 'stress' has also evolved considerably. It is now recognised that there is no 'stereotyped response pattern' to a stressor and an 'understanding of the health consequences of stress requires an integrative approach'.²³

Modern research into stress hyperglycaemia uses a variety of tools including continuous glucose monitoring, genetic and biomarker profiling and glucagon-like peptide I analogue therapy. Despite these sophisticated approaches, basic gaps in knowledge remain. In particular, there is no consensus definition for stress hyperglycaemia and best management in the acute care setting remains unclear.

DISCLAIMER

This article presents independent research partially commissioned by the National Institute for Health Research (NIHR) under the Collaborations for Leadership in Applied Health Research and Care (CLAHRC) programme for Northwest London. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

ACKNOWLEDGEMENTS

This work benefited from the expertise of Estela Dukan who assisted in sourcing relevant historical material and Dr AM Zalin who translated relevant passages within reference 16 from French to English.

REFERENCES

- 1 Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. *Lancet* 2009; 373: 1798–807. [http://dx.doi.org/10.1016/S0140-6736\(09\)60553-5](http://dx.doi.org/10.1016/S0140-6736(09)60553-5)
- 2 Husband DJ, Alberti KG, Julian DG. “Stress” hyperglycaemia during acute myocardial infarction: and indicator of pre-existing diabetes? *Lancet* 1983; 2: 179–81.
- 3 Umpierrez GE, Isaacs SD, Bazargan N et al. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. *J Clin Endocrinol Metab* 2002; 87: 978–82.
- 4 Capes SE, Hunt D, Malmberg K et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. *Lancet* 2000; 355: 773–8.
- 5 Baker EH, Janaway CH, Philips BJ et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. *Thorax* 2006; 61: 284–9.
- 6 Sanders LJ. From Thebes to Toronto and the 21st century: an incredible journey. *Diabetes Spectrum* 2002; 15: 57–60.
- 7 Tattersall R. *Diabetes: The Biography*. Oxford: Oxford University Press; 2009.
- 8 Moal ML. Historical approach and evolution of the stress concept: a personal account. *Psychoneuroendocrinology* 2007; 32: S3–S9.
- 9 Macfarlane I. Mathew Dobson of Liverpool (1735–1784) and the history of diabetes. *Practical Diabetes International* 1990; 7: 246–8.
- 10 Feudtner JC. *Bitter Sweet: Diabetes, Insulin and the Transformation of Illness*. Chapel Hill, NC: University of North Carolina Press; 2003. p. 5
- 11 Gross CG. Claude Bernard and the Constancy of the Internal Environment. *The Neuroscientist* 1998; 4: 380–5.
- 12 Wilson DWD. *Claude Bernard*. Popular Science (Bonnie Corporation). June 1914: 567–78.
- 13 Young FG. Claude Bernard and the discovery of glycogen, a century of retrospect. *Br Med J* 1957: 1431–7.
- 14 Heilbron JL. *The Oxford Companion to the History of Modern Science*. Oxford: Oxford University Press; 2003.
- 15 Jackson M. *The Age of Stress*. Oxford: Oxford University Press; 2013.
- 16 Bernard C. *Leçons de physiologie expérimentale appliquée à la médecine. vol. 1*. Paris: Balliere; 1855. (Fre).
- 17 Benison S, Barger AC, Wolfe EL, Walter B. *Cannon. The Life and Times of a Young Scientist*. Cambridge, MA: Belknap Press of Harvard University Press; 1987.
- 18 Bhattacharyya KB. *Eminent Neuroscientists: Their Lives and Works*. West Bengal: Academic Publishers; 2012.
- 19 Lescoufflair E. *Walter Bradford Cannon: experimental physiologist 1871-1945. Notable American Unitarians 1936-1961*. Harvard Square Library; 2007. p.41
- 20 Cooper SJ. From Claude Bernard to Walter Cannon. Emergence of the concept of homeostasis. *Appetite* 2008; 51: 419–27. <http://dx.doi.org/10.1016/j.appet.2008.06.005>
- 21 Cannon B. Walter Bradford Cannon: Reflections on the man and his contributions. *Int J Stress Manag* 1994; 1: 145–58.
- 22 Cannon WB. *Bodily Changes in Pain, Hunger, Fear and Rage*. New York, NY: D Appleton & Co.; 1915.
- 23 Goldstein DS, Irwin JK. Evolution of concepts of stress. *Stress* 2007; 10: 109–120.
- 24 Cannon WB. *The Wisdom of the Body*. New York, NY: WW Norton & Company; 1932.
- 25 Gerard RW. Is the age of heroes ended? In: Brooks CM, Koizumi K, Pinkston JO, editors. *The Life and Contributions of Walter Bradford Cannon 1871–1945*. New York, NY: Downstate Medical Center, Brooklyn; 1975: 197–208.
- 26 Selye H. The general adaptation syndrome. *Annu Rev Med* 1951; 2: 327–42.
- 27 Kellaway CH. The hyperglycaemia of asphyxia and the part played therein by the suprarenals. *J Physiol* 1919; 53: 211–35.
- 28 Forster MG. The effect of splanchnotomy and of phlorrhizin on decerebration hyperglycaemia. *J Physiol* 1933; 80: 323–8.
- 29 De Bodo RC, Bloch HI, Gross IH. The role of the anterior pituitary in adrenaline hyperglycaemia and liver glycogenolysis. *Am J Physiol* 1942; 137: 124–35.
- 30 Mylon E, Cashman Jr. CW, Winternitz MC. The relation of adrenaline and of the carotid sinus to the hyperglycaemia of shock. *Am J Physiol* 1944; 142: 638–47.
- 31 Mirsky IA. Emotional hyperglycemia. *Proc Annu Meet Cent Soc Clin Res US* 1946; 19: 74.
- 32 McLean FC. The sugar-content of the blood and the clinical significance. *JAMA* 1914; 12: 917–20. <http://dx.doi.org/10.1001/jama.1914.02560370025014>
- 33 Levine SA. Angina pectoris: some clinical considerations. *JAMA* 1922; 79: 928–33. <http://dx.doi.org/10.1001/jama.1922.02640120002002>
- 34 Levine SA. Coronary thrombosis: its various clinical features. *Medicine* 1929; 8: 245.
- 35 Cruickshank N. Coronary thrombosis and myocardial infarction with glycosuria. *Br Med J* 1931; 1: 618–9.
- 36 Scherf D. Hyperglycaemia and glycosuria in coronary thrombosis. *Wein Klin Wochenschr* 1933; 46: 69–71.
- 37 Eckerstrom S. Hyperglycémie de type transitoire et glycosuria consecutives a un infarctus du myocarde. *Acta Med Scand* 1938; 95: 528–38.
- 38 Gottsegen G. Coronarthrombose und diabetes. *Arch f. Verdauungskrankheiten* 1933; 53: 36–40.
- 39 Raab AP, Rabinowitz MA. Glycosuria and hyperglycemia in coronary thrombosis. *JAMA* 1936; 106: 1705–8. <http://dx.doi.org/10.1001/jama.1936.02770200011004>
- 40 Spuhler OV. Herzinfarkt, Pankreas, und Kohlehydratstoffwechselstörungen. *Schweiz Med Wochenschr* 1943; 73: 1458.
- 41 Goldberger E, Alesio J, Woll F. The significance of hyperglycemia in myocardial infarction. *New York State J Med* 1945; 45: 391–3.
- 42 Eckerstrom S. Clinical and prognostic aspects of acute coronary occlusion. *Acta Med Scand* 1951; 250: 11–107.
- 43 Gitelson S. The blood pyruvic acid level in patients with stress hyperglycaemia and diabetes mellitus. *Acta Endocrinol* 1956; 22: 87–94.
- 44 Datey KK, Nanda NC. Hyperglycemia after acute myocardial infarction. Its relation to diabetes mellitus. *N Eng J Med* 1967; 276: 262–5. <http://dx.doi.org/10.1056/NEJM196702022760504>
- 45 Gitelson S, Tiberin P. Effect of emotional stress on the blood pyruvic acid level. *Acta Endocrinol* 1952; 11: 345–50.
- 46 Wong CKY, Wong V, Ho JT et al. High cortisol levels in hyperglycaemia myocardial infarct patients signify stress hyperglycaemia and predict subsequent normalization of glucose tolerance. *Clin Endocrinol* 2010; 72: 189–95. <http://dx.doi.org/10.1111/j.1365-2265.2009.03654.x>
- 47 Ellenberg M, Osseman KE, Pollack H. Hyperglycaemia in coronary thrombosis. *Diabetes* 1952; 1: 16–21.
- 48 Camerini-Dávalos RA, Cole HS. *Early Diabetes: Advances in Metabolic Disorders, Volume 1*. New York, NY: Academic Press 2013
- 49 Fajan SJ, Conn JW. An approach to the prediction of diabetes mellitus by modification of the glucose tolerance test with cortisone. *Diabetes* 1954; 3: 296–304.
- 50 Gray CS, Scott JF, French JM et al. Prevalence and prediction of unrecognized diabetes mellitus and impaired glucose tolerance following acute stroke. *Age Ageing* 2004; 33: 71–7.
- 51 Dave JA, Engel ME, Freercks R et al. Abnormal glucose metabolism in non-diabetic patients presenting with an acute stroke: prospective study and systematic review. *QJM* 2010; 103: 495–503. <http://dx.doi.org/10.1093/qjmed/hcq062>
- 52 Duncan JM. On puerperal diabetes. *Trans Obstet Soc Lond* 1882; 24: 256–85.
- 53 Coustan DR. Gestational diabetes mellitus. *Clin Chem* 2013; 59: 1310–21. <http://dx.doi.org/10.1373/clinchem.2013.203331>

- 54 Jackson WPU. Studies in pre-diabetes. *Br Med J* 1952; 3: 690–6.
- 55 Damm P. Future risk of diabetes in mother and child after gestational diabetes mellitus. *Int J Gynecol Obstet* 2009; 104: 525–6. <http://dx.doi.org/10.1016/j.ijgo.2008.11.025>
- 56 Sutherland HW, Stowers JM, O'Sullivan JB. Subsequent morbidity among gestational diabetic women. In: Sutherland HW, Stowers JM, eds. *Carbohydrate Metabolism in Pregnancy and the Newborn*. New York: Churchill Livingstone; 1984: p.174–80.
- 57 McCance D, Maresh M, Sacks D. *A Practical Manual of Diabetes in Pregnancy*. Chichester: John Wiley & Sons; 2013
- 58 Williams JW. The clinical significance of glycosuria in pregnant women. *Am J Med Sci* 1909; 137: 1–26.
- 59 Opie LH. Acute metabolic response in myocardial infarction. *Br Heart J* 1971; 33: 129–37.
- 60 Sewdarsen M, Jialel I, Vythilingum S et al. Stress hyperglycaemia is a predictor of abnormal glucose tolerance in Indian patients with acute myocardial infarction. *Diabetes Res* 1987; 1: 47–9.
- 61 Greci LS, Kailasam M, Malkani S et al. Utility of HbA1c Levels for Diabetes Case Finding in Hospitalized Patients With Hyperglycemia. *Diabetes Care* 2003; 26: 1064–8.
- 62 Yudkin JS, Oswald GA. Stress hyperglycemia and cause of death in non-diabetic patients with myocardial infarction. *Br Med J (Clin Res Ed)* 1987; 294: 773.
- 63 Melamed E. Reactive hyperglycaemia in patients with acute stroke. *J Neurol Sci* 1976; 29: 267–75.
- 64 Pulsinelli WA, Levy DE, Sigsbee B et al. Increased damage after ischemic stroke in patients with hyperglycemia with or without established diabetes mellitus. *Am J Med* 1983; 74: 540–4.
- 65 Woo E, Chan YW, Yu YL et al. Admission glucose level in relation to mortality and morbidity outcome in 252 stroke patients. *Stroke* 1988; 19: 185–91.
- 66 Woo J, Lam CWK, Kay R et al. The influence of hyperglycemia and diabetes mellitus on immediate and 3-month morbidity and mortality after acute stroke. *Arch Neurol* 1990; 47: 1174–7.
- 67 O'Neill PA, Davies I, Fullerton KJ et al. Stress hormone and blood glucose response following acute stroke in the elderly. *Stroke* 1991; 22: 842–7.
- 68 Kiers L, Davis SM, Larkins R et al. Stroke topography and outcome in relation to hyperglycaemia and diabetes. *J Neurol Neurosurg Psychiatry* 1992; 55: 263–70.
- 69 Weir CJ, Murray GD, Dyker AG et al. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. *BMJ* 1997; 314: 1303–6.
- 70 Murros K, Fogelholm R, Kettunen S et al. Serum cortisol and outcome of ischaemic brain infarction. *J Neurol Sci* 1993; 116: 12–7.
- 71 Myers MG, Norris JW, Haczinski VC et al. Plasma norepinephrine in stroke. *Stroke* 1981; 12: 200–4.
- 72 Riddle MC, Hart J. Hyperglycaemia recognized and unrecognized as a risk factor for stroke and transient ischaemic attacks. *Stroke* 1982; 13: 356–9.
- 73 Scott JF, Robinson GM, French JM et al. Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycaemia. *Stroke* 1999; 30: 793–9.
- 74 McAlister FA, Majumdar SR, Blitz S et al. The relation between hyperglycaemia and outcomes in 2471 patients admitted to the hospital with community-acquired pneumonia. *Diabetes Care* 2005; 28: 810–5.
- 75 Capes SE, Hunt D, Malmberg K et al. Stress hyperglycaemia and prognosis of stroke in nondiabetic and diabetic patients. *Stroke* 2001; 32: 2426–32.
- 76 Mebazza A, Gayat E, Lassus J et al. Association between elevated blood glucose and outcome in acute heart failure. *J Am Coll Cardiol* 2013; 61: 820–9. <http://dx.doi.org/10.1016/j.jacc.2012.11.054>
- 77 Leonidou L, Mouzaki A, Michalaki M et al. Cytokine production and hospital mortality in patients with sepsis-induced hyperglycaemia. *J Infect* 2007; 55: 340–6.
- 78 Van de Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in critically ill patients. *N Eng J Med* 2001; 345: 1359–67.
- 79 Egi M, Bellomo R, Stachowski E et al. Blood glucose concentration and outcome of critical illness: the impact of diabetes. *Crit Care Med* 2008; 36: 2249–55. <http://dx.doi.org/10.1097/CCM.0b013e318181039a>
- 80 Rady MY, Johnson DJ, Patel BM et al. Influence of individual characteristics on outcome of glycaemic control in intensive care unit patients with or without diabetes mellitus. *Mayo Clin Proc* 2005; 80: 1558–67.
- 81 Arabi YM, Dabbagh OC, Tamim HC et al. Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients. *Crit Care Med* 2008; 36: 3190–7. <http://dx.doi.org/10.1097/CCM.0b013e31818f21aa>
- 82 Van den Berghe G, Wilmer A, Hermans G et al. Intensive insulin therapy in the medical ICU. *N Eng J Med* 2006; 354: 449–61.
- 83 Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. *JAMA* 2008; 300: 933–44. <http://dx.doi.org/10.1001/jama.300.8.933>
- 84 Griesdale DEG, de Souza RJ, van Dam RM et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. *CMAJ* 2009; 180: 821–7. <http://dx.doi.org/10.1503/cmaj.090206>
- 85 Preiser JC. NICE-SUGAR: the end of a sweet dream? *Critical Care* 2009; 13: 143. <http://dx.doi.org/10.1186/cc7790>
- 86 The NICE-SUGAR study investigators. Intensive versus conventional glucose control in critically ill patients. *N Eng J Med* 2009; 360: 1283–97. <http://dx.doi.org/10.1056/NEJMoa0810625>
- 87 Krinsley JS. Glycaemic control, diabetes status and mortality in a heterogeneous population of critically ill patients before and during the era of intensive glycaemic management: six and one-half years experience at a university-affiliated community hospital. *Semin Thorac Cardiovasc Surg* 2006; 18: 317–25.
- 88 Umpierrez GE, Isaacs SD, Bazargan N et al. Hyperglycaemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. *J Clin Endocrinol Metab* 2002; 87: 978–82.
- 89 Kosiborod M, Rathore SS, Inzucchi SE et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction. *Circulation* 2005; 111: 3078–86.
- 90 Petursson P, Herlitz J, Caidahl K et al. Admission glycaemia and outcome after acute coronary syndrome. *Int J Cardiol* 2007; 116: 315–20.
- 91 Ishihara M, Kagawa E, Inoue I et al. Impact of admission hyperglycaemia and diabetes mellitus on short- and long-term mortality after acute myocardial infarction in the coronary intervention era. *Am J Cardiol* 2007; 99: 1674–9.
- 92 Schiele F, Descotes-Genon V, Seronde MF et al. Predictive value of admission hyperglycaemia on mortality in patients with acute myocardial infarction. *Diabet Med* 2006; 23: 1370–6.
- 93 Bauters C, Ennezat PV, Tricot O et al. Stress hyperglycaemia is an independent predictor of left ventricular remodeling after first anterior myocardial infarction in non-diabetic patients. *Eur Heart J* 2007; 28: 546–52.
- 94 Sanjuan R, Núñez J, Blasco ML et al. Prognostic implications of stress hyperglycaemia in acute ST elevation myocardial infarction. Prospective observational study. *Rev Esp Cardiol* 2011; 64: 210–7. <http://dx.doi.org/10.1016/j.recesp.2010.08.002>
- 95 Stojković A, Koracević G, Perišić Z et al. [The influence of stress hyperglycemia on the prognosis of patients with acute myocardial infarction and temporary electrical cardiac pacing]. *Srp Arh Celok Lek* 2010; 138: 430–5.
- 96 Bronisz A. Stress hyperglycemia in patients with first myocardial infarction. *International J Clin Pract* 2012; 66: 592–601. <http://dx.doi.org/10.1111/j.1742-1241.2012.02917.x>
- 97 Carmen Wong KY, Wong V, Ho JT et al. High cortisol levels in hyperglycaemic myocardial infarct patients signify stress hyperglycaemia and predict subsequent normalization of glucose tolerance. *Clin Endocrinol* 2010; 72: 189–95. <http://dx.doi.org/10.1111/j.1365-2265.2009.03654.x>
- 98 Hadjadj S, Coisne D, Mauco G et al. Prognostic value of admission plasma glucose and HbA1c in acute myocardial infarction. *Diabet Med* 2004; 21: 305–10.

- 99 Sodi-Pallares D, Testelli MR, Fishleder BL et al. Effects of intravenous infusion of potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. *Am J Cardiol* 1962; 9: 166–181.
- 100 Malmberg K, Rydén L, Efendic S et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. *J Am Coll Cardiol* 1995; 26: 57–65.
- 101 Malmberg K, Rydén L, Wedel H et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. *Eur Heart J* 2005; 26: 650–61.
- 102 Cheung NW, Wong VW, McLean M. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. *Diabetes Care* 2006; 29: 765–70.
- 103 Mehta SR, Yusuf S, Díaz R et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. *JAMA* 2005; 293: 437–46.
- 104 Egom EE. A therapeutic approach to hyperglycaemia in the setting of acute myocardial infarction: spotlight on glucagon-like peptide 1. *Ther Adv Cardiovasc Dis* 2012; 6: 213–9. <http://dx.doi.org/10.1177/1753944712457598>
- 105 McGregor AK, Leech N, Purcell IF et al. Effect of primary percutaneous coronary intervention on stress hyperglycaemia in myocardial infarction. *Diabet Med* 2012; 29: 1317–20. <http://dx.doi.org/10.1111/j.1464-5491.2012.03666.x>
- 106 Baker EH, Janaway CH, Philips BJ et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic pulmonary disease. *Thorax* 2006; 61: 284–9.
- 107 Balasanthiran A, Zalin B, Baker EH et al. Hyperglycaemia in the acute care setting. *Clin Med* 2012; 12: 272–5.
- 108 Lepper PM, Ott S, Nüesch E et al. Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study. *BMJ* 2012; 344: e3397. <http://dx.doi.org/10.1136/bmj.e3397>
- 109 Schuetz P, Friedli N, Grolimund E et al. Effect of hyperglycaemia on inflammatory and stress responses and clinical outcome of pneumonia in non-critical-care inpatients: results from an observational cohort study. *Diabetologia* 2013; 57: 275–84. <http://dx.doi.org/10.1007/s00125-013-3112-9>
- 110 Parsons M, Barber AP, Desmond PM et al. Acute hyperglycemia adversely affects stroke outcome: A magnetic resonance imaging and spectroscopy study. *Ann Neurol* 2002; 52: 20–8.
- 111 Shao B, Bayraktutan U. Hyperglycaemia promotes cerebral barrier dysfunction through activation of protein kinase C-β. *Diabetes Obes Metab* 2013; 15: 993–9. <http://dx.doi.org/10.1111/dom.12120>
- 112 Lindsberg PJ. Hyperglycaemia in acute stroke. *Stroke* 2004; 35: 363–4.
- 113 Allport L, Baird T, Butcher K et al. Frequency and temporal profile of poststroke hyperglycaemia using continuous glucose monitoring. *Diabetes Care* 2006; 29: 1839–44.
- 114 Vibo R, Kõrv J, Roose M. One-year outcome after first-ever stroke according to stroke subtype, severity, risk factors and pre-stroke treatment: a population-based study from Tartu Estonia. *Eur J Neurol* 2007; 14: 435–39.
- 115 Farrokhnia NI, Björk E, Lindbäck J et al. Blood glucose in acute stroke, different therapeutic targets for diabetic and non-diabetic patients? *Acta Neurol Scand* 2005; 112: 81–7.
- 116 Fogelholm R, Murros K, Rissanen A et al. Admission blood glucose and short term survival in primary intracerebral haemorrhage: a population based study. *J Neurol Neurosurg Psychiatry* 2005; 76: 349–53.
- 117 Samiullah S, Qasim R, Imran S et al. Frequency of stress hyperglycaemia and its influence on the outcome of patients with spontaneous intracerebral haemorrhage. *J Pak Med Assoc* 2010; 60: 660–3.
- 118 Bruno A, Biller J, Adams HP Jr et al. Acute blood glucose level and outcome from ischaemic stroke. Trial of ORG 10172 in acute stroke treatment (TOAST) investigators. *Neurology* 1999; 52: 280–4.
- 119 Bruno A, Levine SR, Frankel MR et al. Admission glucose level and clinical outcomes in the NINDS rt-PA stroke trial. *Neurology* 2002; 59: 669–74.
- 120 Uyttenboogaart M, Koch MW, Stewart RE et al. Moderate hyperglycaemia is associated with favourable outcome in acute lacunar stroke. *Brain* 2007; 130: 1626–30.
- 121 Fang Y, Zhang S, Wu B et al. Hyperglycaemia in acute lacunar stroke: a Chinese hospital-based study. *Diab Vasc Dis Res* 2013; 10: 216–21. <http://dx.doi.org/10.1177/1479164112459663>
- 122 McCormick MT, Muir KV, Gray CS et al. Management of hyperglycaemia in acute stroke how, when and for whom? *Stroke* 2008; 39: 2177–85. <http://dx.doi.org/10.1161/STROKEAHA.107.496646>
- 123 Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. *Am J Cardiol* 1974; 34: 29–34.
- 124 Barsheshet A, Garty M, Grossman E et al. Admission blood glucose level and mortality among hospitalized nondiabetic patients with heart failure. *Arch Intern Med* 2006; 166: 1613–9.
- 125 Helfand B, Maselli N, Lessard D et al. Elevated serum glucose levels and survival after acute heart failure: a population-based perspective. *Diab Vasc Dis Res* 2015; 12: 119–25. <http://dx.doi.org/10.1177/1479164114559024>
- 126 Sud M, Wang X, Austin PC et al. Presentation blood glucose and death, hospitalization and future diabetes risk in patients with acute heart failure syndromes. *Eur Heart J* 2015; 36: 924–31. <http://dx.doi.org/10.1093/eurheartj/ehu462>
- 127 Kosiborod M, Inzucchi SE, Spertus JA et al. Elevated admission glucose and mortality in elderly patients hospitalized with heart failure. *Circulation* 2009; 119: 1899–907. <http://dx.doi.org/10.1161/CIRCULATIONAHA.108.821843>
- 128 Dungan K. Glycaemic control and variability for congestive heart failure exacerbation. <http://www.clinicaltrials.gov/ct2/show/study/NCT00812487?term=heart+failure+and+hyperglycaemia&rank=6§=X01256> (accessed 4/8/15).
- 129 O'Sullivan EP, Duignan J, O'Shea P et al. Evaluating hyperglycaemia in the hospitalized patient: towards an improved system for classification and treatment. *Ir J Med Sci* 2014; 183: 65–9. <http://dx.doi.org/10.1007/s11845-013-0973-3>
- 130 Marik PE, Bellomo R. Stress hyperglycaemia: an essential survival response! *Crit Care* 2013; 17: 305. <http://dx.doi.org/10.1186/cc12514>
- 131 Van Cromphaut SJ. Hyperglycaemia as part of the stress response: the underlying mechanisms. *Best Pract Res Clin Anaesthesiol* 2009; 23: 375–86.